BACKGROUND AND AIMS: Landiolol is an ultrashort-acting, highly cardio-selective beta1-adrenergic receptor blocker used for short-term control of tachyarrhythmias. While its real-world use has been described in Japan, data from European clinical practice are lacking. This study aimed to collect real-world data on landiolol use, effectiveness, and safety across diverse clinical settings in Europe. METHODS: This multicentre, observational study included adult patients with supraventricular arrhythmias treated with landiolol. Patient characteristics, drug utilization patterns, efficacy, and safety were assessed. RESULTS: In total, 450 patients were enrolled and 449 analysed (median age: 72 years, IQR 63-78) from 17 sites across eight European countries. Most patients (73.1%) received landiolol for atrial fibrillation. Median (IQR) duration of infusion was 8.9 (2.3. - 34.0) hours, with starting, minimum, and maximum doses of 5.3 (2.5 - 10.0), 4.0 (1.7-10) and 10.0 (6.0-30.0) µg/kg/min, respectively. Heart rate (HR) control, defined as HR ≤110 bpm or a reduction of >20% from baseline, was achieved in 74.2% of patients within 4 hours after treatment discontinuation, with 36.9% of arrhythmia patients restoring sinus rhythm. Blood pressure (BP) remained stable throughout treatment. A total of 123 adverse events and 113 major adverse cardiac events were reported, none related to landiolol. CONCLUSIONS: In European clinical practice, landiolol dosing adhered to product information recommendations. Landiolol was effective in controlling HR with minimal impact on BP. The treatment was well tolerated, and no new safety signals were identified. These findings support the efficacy and safety of landiolol across diverse clinical settings in Europe.

AOP Health International Management AG Industriering 20 9491 Ruggell Liechtenstein

AOP Orphan Pharmaceuticals GmbH Leopold Ungar Platz 2 1190 Vienna Austria

Clinical Department of Anesthesiology and Intensive Therapy Wroclaw Medical University Borowska St 213 50 556 Wroclaw Poland

Department of Cardiology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Úvalu 84 1 Prague 15006 Czech Republic

Department of Internal Medicine and Cardiology Heart Center Dresden Technische Universität Dresden Dresden Germany

General Hospital of Nikaia Intensive Care Unit St Mantouvalou 3 18454 Greece

Institute for Clinical and Experimental Medicine Cardiology Department Vídeňská 1958 9 140 21 Prague Czech Republic

Klinikum Wels Grieskirchen GmbH Institut für Anästhesiologie und Intensivmedizin Grieskirchner Straße 42 4600 Wels Austria

Konstantopouleio Patision General Hospital 3 5 Agias Olgas Street Nea Ionia 142 33 Athens Greece

Medical Centre Leeuwarden Henri Dunantweg 2 8934 AD Leeuwarden The Netherlands

Medical University of Graz Division of Cardiology Auenbruggerplatz 15 8036 Graz Austria

Medical University of Vienna Department of Cardiology Währinger Gürtel 18 20 1090 Vienna Austria

Medical University of Vienna Department of Clinical Pharmacology Währinger Gürtel 18 20 1090 Vienna Austria

National and Kapodistrian University of Athens Medical school Department of Pulmonary and Intensive Care Evangelismos Hospital 45 47 Ipsilandou Street 106 75 Athens Greece

Ordensklinikum Linz GmbH Elisabethinen Fadingerstraße 1 4020 Linz Austria

Poznan University of Medical Sciences Department of Cardiology Dluga 1 2 61 848 Poznan Poland

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie Jaczewskiego 8 20 954 Lublin Poland

Semmelweis University Heart and Vascular Center H 1122 Budapest Városmajor Str 68 Hungary

Szpital Wojewódzki w Poznaniu Department of Anesthesiology and intensive care medicine ul Juraszów 7 19; 60 647 Poznań Poland

University Medical Centre Ljubljana Internal Clinic Zaloška 2 SI 1000 Ljubljana Slovenia

Citace poskytuje Crossref.org